NDAORALTABLET
Approved
Sep 2014
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
6
Data completeness
6/8 — Strong
AURYXIA (ferric citrate) by Ipsen is phosphate. First approved in 2014.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AURYXIA (ferric citrate) is an oral iron-based phosphate binder and iron replacement therapy approved for chronic kidney disease patients. It binds phosphate in the gastrointestinal tract to lower serum phosphate levels while simultaneously delivering bioavailable iron to treat iron deficiency anemia. The ferric iron is reduced to ferrous form in the GI tract, absorbed, and incorporated into hemoglobin via transferrin binding.
$0.183BPart D
Peak3.8 years to LOEPeak-stage product with substantial Medicare utilization (97K+ claims) suggests established sales infrastructure and stable team headcount through mid-2030s.
Mechanism of Action
phosphate. This compound is insoluble and is excreted in the stool. By binding phosphate in the GI tract and decreasing absorption, ferric citrate lowers the phosphate concentration in the serum. Iron Deficiency Anemia in Chronic Kidney Disease Not on Dialysis Ferric iron is reduced from the ferric…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (6)
Ferric Citrate and Chronic Kidney Disease in Children
Started Jun 2022
160 enrolled
Chronic Kidney Diseases
Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease
Started Mar 2022
289 enrolled
Anemia, Iron DeficiencyHyperphosphatemiaRenal Insufficiency, Chronic+4 more
Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants
Started Jun 2021
214 enrolled
HyperphosphatemiaAnemia, Iron DeficiencyRenal Insufficiency
PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD
Started Oct 2020
141 enrolled
Anemia of Chronic Kidney Disease
Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
Started Jun 2019
240 enrolled
HyperphosphatemiaEnd Stage Renal DiseaseESRD
Worked on AURYXIA at Ipsen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.